-
Track & Monitor
Innovation in pharma: T-cell binding fusion peptides
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the pharma industry’s T-cell binding fusion peptides segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered...
-
Track & Monitor
Immuno-oncology in pharma: cancer immunotherapy
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the pharma industry’s cancer immunotherapy segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based on...
-
Thematic Analysis
Precision and Personalized Medicine in Pharma – Thematic Intelligence
Precision and Personalized Medicine in Pharma Thematic Report Overview Precision and personalized medicine have already begun to reshape disease treatment paradigms and the provision of healthcare. Improved patient outcomes, increased quality of life, reduced financial and time expenditure of disease management with curative therapies, and a shift from reactive to proactive care are all driving investment in R&D in this space. The precision and personalized medicine in pharma thematic intelligence report provides a focused chapter on the key healthcare, technology,...
-
Sector Analysis
Multiple Myeloma – Cell Therapies 15-Market Assessment and Sales Forecast to 2031
Multiple Myeloma Cell Therapy Market Report Overview The total market value for the 15M, which includes both cell therapies and established/traditional MM therapies was $25.7 billion in 2021. The following are some of the key highlights of the multiple myeloma cell therapy market: The market growth will be attributed to the established CAR-T agents such as Abecma and Carvykt. The success of CAR-Ts in MM has fueled R&D investment into this class of therapy, with more CAR-Ts in development than...
-
Product Insights
Multiple Myeloma (Kahler Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Multiple Myeloma Pipeline Products Market Report Overview Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. It mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain, and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery. The Multiple Myeloma Drugs in Development market research...
-
Product Insights
Glioblastoma Multiforme (GBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Glioblastoma Multiforme Pipeline Drugs Market Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness, and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy, and chemotherapy. The Glioblastoma Multiforme (GBM) drugs in development market research report provides comprehensive information on the therapeutics under...
-
Track & Monitor
Immuno-oncology in Pharmaceuticals: CAR-T cell-based compositions
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s CAR-T cell-based compositions segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
Track & Monitor
Immuno-oncology in Pharmaceuticals: In-vitro T-cell activation
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s In-vitro T-cell activation segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
Track & Monitor
Innovation in Pharmaceuticals: Cytokine activate T-cell based compositions
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Cytokine activate T-cell based compositions segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or...
-
Track & Monitor
Biosimilars in Pharmaceuticals: Recombinant antibodies for cytotoxic T-cells
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Recombinant antibodies for cytotoxic T-cells segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or...